Marinus Pharmaceuticals, Inc.
NASDAQ:MRNS
Overview | Financials
Company Name | Marinus Pharmaceuticals, Inc. |
Symbol | MRNS |
Currency | USD |
Price | 0.359 |
Market Cap | 19,775,156 |
Dividend Yield | 0% |
52-week-range | 0.26 - 11.26 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Scott N. Braunstein M.D. |
Website | https://marinuspharma.com |
An error occurred while fetching data.
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD